Guidelines Panel Meeting: Salvage Therapy for Prostate Cancer (2023)
Panel members will be reviewing evidence prepared and presented by a methodologist who has been extracting and analyzing data from research articles. The panelists will inquire about aspects of the evidence and the methodologists will provide explanations. The panel will discuss the evidence and deliberate on the best practice methods of salvage therapy for prostate cancer.
This activity is limited to Salvage Therapy for Prostate Cancer Guidelines Panel Members only.
After completing this activity, participants will be able to:
- Analyze the latest scientific evidence for salvage therapy for of prostate cancer.
- Recommend appropriate methods of therapy for prostate cancer in the salvage setting.
- Apply improved critical thinking skills to medical literature reviews.
Tuesday, January 17th, 2023
6:00-6:10pm Welcome and Introductions Sennett Kim
6:10-6:20pm Conflict of Interest Disclosures and Panel Responsibilities Sennett Kim
6:20-8:45pm OHSU Evidence Overview Dr. Chou
Tuesday, March 21st, 2023
10:00-10:15am Introduction to review of Statement Development Dr. Morgan, MD
10:15am-12:45pm Guideline Statement Development Panel
Tuesday, April 11th, 2023
6:00-8:45pm Continue Guideline Statement Development Panel
8:45-9:00pm Questions/Comments and Next Steps
*All Eastern Time
Guideline Panel Chair
|Name||Company Name||Relationship Type||End Date|
|Morgan, Todd Matthew||MDxHealth||Scientific Study or Trial||02/24/2022|
|Morgan, Todd Matthew||Myriad Genetics||Scientific Study or Trial||12/31/2021|
|Morgan, Todd Matthew||Blue Earth||Consultant or Advisor||02/28/2021|
|Morgan, Todd Matthew||Stratify Genomics||Consultant or Advisor||03/03/2021|
|Morgan, Todd Matthew||Myovant Biosciences||Consultant or Advisor||11/01/2021|
|Morgan, Todd Matthew||Tempus||Consultant or Advisor||12/17/2021|
|Name||Company Name||Relationship Type||End Date|
|Chou, Roger||Nothing to disclose|
COI Review Work Group
AUA staff have nothing to disclose.
All relevant financial relationships have been mitigated.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of 9.0 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial (aka ineligible company) interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 9.00 AMA PRA Category 1 Credit™
- 9.00 Non-Physician Participation